Decreased Deposition of Beta-Amyloid 1-38 and Increased Deposition of Beta-Amyloid 1-42 in Brain Tissue of Presenilin-1 E280A Familial Alzheimer’s Disease Patients

Felix Dinkel¹, Diana Trujillo-Rodriguez², Andres Villegas³, Johannes Streffer⁴, Marc Mercken⁴, Francisco Lopera³, Markus Glatzel¹ and Diego Sepulveda-Falla¹*†

¹ Institute of Neuropathology, University Medical Center Hamburg-Eppendorf – UKE, Hamburg, Germany, ² Genetics Institute, National University of Colombia, Bogotá, Colombia, ³ Neuroscience Group of Antioquia, Faculty of Medicine, University of Antioquia, Medellín, Colombia, ⁴ Johnson & Johnson Pharmaceutical Research and Development, Janssen Pharmaceutica, Beerse, Belgium

Familial Alzheimer’s Disease (FAD) caused by Presenilin-1 (PS1) mutations is characterized by early onset, cognitive impairment, and dementia. Impaired gamma secretase function favors production of longer beta-amyloid species in PS1 FAD. The PS1 E280A mutation is the largest FAD kindred under study. Here, we studied beta-amyloid deposits in PS1 E280A FAD brains in comparison to sporadic Alzheimer’s disease (SAD). We analyzed cortices and cerebellum from 10 FAD and 10 SAD brains using immunohistochemistry to determine total beta-amyloid, hyperphosphorylated tau (pTau), and specific beta-amyloid peptides 1-38, 1-40, 1-42, and 1-43. Additionally, we studied beta-amyloid subspecies by ELISA, and vessel pathology was detected with beta-amyloid 1-42 and truncated pyroglutamylated beta-amyloid antibodies. There were no significant differences in total beta-amyloid signal between SAD and FAD. Beta-amyloid 1-38 and 1-43 loads were increased, and 1-42 loads were decreased in frontal cortices of SAD when compared to FAD. Beta-amyloid species assessment by ELISA resembled our findings by immunohistochemical analysis. Differences in beta-amyloid 1-38 and 1-42 levels between SAD and FAD were evidenced by using beta-amyloid length-specific antibodies, reflecting a gamma secretase-dependent shift in beta-amyloid processing in FAD cases. The use of beta-amyloid length-specific antibodies for postmortem assessment of beta-amyloid pathology can differentiate between SAD and PS1 FAD cases and it can be useful for identification of SAD cases potentially affected with gamma secretase dysfunction.

Keywords: beta-amyloid, Presenilin-1, gamma Secretase, familial Alzheimer’s Disease, immunohistochemistry, tau

INTRODUCTION

Alzheimer's disease (AD) is the most common form of dementia in the elderly. The prevalence is estimated to be about 24 to 35 million people worldwide (Reitz and Mayeux, 2014). Clinically, it is characterized by progressive cognitive impairment and behavioral changes, which eventually lead to dementia and death (Giaccone et al., 2011). Neuropathological hallmarks are brain atrophy,
beta-amyloid (Aβ) deposits forming plaques in the extracellular space and the accumulation of intraneuronal hyperphosphorylated tau protein (pTau) as neurofibrillary tangles (NFTs) (Alzheimer's Association, 2010). Age is one of the main risk factors for developing AD (Berr et al., 2005). AD can be divided into two groups: early onset AD (EOAD) occurring before 65 years of age, while 95% of all AD cases are late onset AD (LOAD) and occur after 65 years of age (Alzheimer’s Association, 2010). The presence of allele 4 of Apolipoprotein E (ApoE4) is the main genetic risk factor for LOAD; ~40% of these patients show at least one ApoE4 allele (Myers et al., 1996; Bettens et al., 2013).

Near to 70% of EOAD are associated with mutations in genes encoding for Amyloid Precursor Protein (APP), Presenilin-1 (PS1), or Presenilin-2 (PS2) (Bertram et al., 2010). More than 190 PS1 pathogenic mutations are the most common cause of familial EOAD (FAD) (Cruts et al., 2012; De Strooper et al., 2012). PS1 is part of the gamma secretase (γ secretase) protein complex, a type 1 intramembrane cleaving protease (Wolfe, 2007; De Strooper et al., 2012) responsible for intramembrane processing of various proteins, including APP (Wakabayashi and De Strooper, 2008; McCarthy et al., 2009). γ secretase acts together with beta secretase in the amyloidogenic processing of APP (De Strooper and Naarreta, 2010), and γ secretase sequentially cleaves it into the 38 to 43 amino acids Aβ peptide (Chávez-Gutiérrez et al., 2012). Aβ aggregate in the extracellular space into fibrils and finally form plaques. Mutated PS1 FAD cases show an elevated amount of Aβ 1-42 and increased Aβ 1-42/1-40 ratio (Larner, 2013). Aβ 1-42 is more prone to aggregate than Aβ 1-40 due to its higher hydrophobicity (Wolfe, 2007; Fernandez et al., 2014). Longer Aβ species, particularly Aβ 1-43, have been reported as being more toxic in vivo, contributing to neurodegeneration in AD (Burnouf et al., 2015), and CSF assessment of Aβ species ratios provides increased diagnostic value together with Amyloid PET studies (Adamczuk et al., 2015). Besides the variable length, Aβ goes through posttranslational modifications such as the formation of N-terminal pyroglycamatates (pE) of truncated Aβ species (Cabrera et al., 2018) with direct impact on Aβ pathogenicity (Sofola-Adesakin et al., 2016). The neuropathological phenotype of PS1 FAD mutations is diverse, including abundant Aβ 1-42 and pTau deposits, prominent atrophy, and neuronal loss. Some PS1 mutations show large diffuse Aβ 1-42-rich cotton wool plaques (Shepherd et al., 2009); others show cerebellar amyloid deposits (Lemere et al., 1996).

Clinically, PS1 FAD is characterized by variable yet early disease onset and full penetrance. Symptoms might include myoclonus, seizures or epileptic syndromes, extrapyramidal symptoms, behavioral and psychiatric features, spastic paraparesis, language impairment, and cerebellar ataxia. Neuropathologically, aside from typical AD features, some PS1 mutations show cotton wool plaques, cerebral amyloid angiopathy (CAA), Lewy bodies, cerebellar Aβ deposition, and Pick bodies (Larner, 2013). In Antioquia, Colombia, a large kindred of FAD with a PS1-E280A mutation has shown early onset of disease, language difficulties, cerebellar ataxia, seizures, and myoclonus (Sepulveda-Falla et al., 2012). Neuropathological studies have shown faster rates of NFTs formation (Gómez-Isla et al., 1999), high neuronal loss, and increased Aβ 1-42 levels with cerebellar pathology (Shepherd et al., 2009), specific pTau aggregation in the cerebellum (Sepulveda-Falla et al., 2011), and Purkinje cell loss (Sepulveda-Falla et al., 2014).

Given that abnormal Aβ processing into longer Aβ species is a known feature in PS1 FAD (Chávez-Gutiérrez et al., 2012) and in PS1 E280A (Van Vickle et al., 2008), we studied morphology and distribution profiles of different Aβ species in brain regions of PS1 E280A FAD patients to make a direct comparison with SAD brain tissue. We found a specific Aβ 1-38/1-42 immunohistochemical profile associated with FAD when compared with SAD and decreased Aβ 1-42/3pE-x ratio of affected vessels in FAD.

**MATERIALS AND METHODS**

**Patients and Human Brain Samples**

Presenilin-1 E280A genealogy was identified 30 years ago and mutation carriers have been followed up since then. Carriers for the present study were identified and affected patients went through neurological and neuropsychological characterization and were followed up using the CERAD protocol, NINCDS-ARDA, and DSM-IV criteria until end-stage dementia and death (Acosta-Baena et al., 2011; Sepulveda-Falla et al., 2011). For neuropathological studies, we collected postmortem brain tissue of 10 PS1-E280A patients and matched them with 10 SAD patients (Table 1) showing corresponding CERAD and Braak stages (Braak and Braak, 1991; Gearing et al., 1995) (neuropathological analyses were performed by MG and DSF, Table 1). Brain donation and procedures were performed following ethical approval from respective institutions (Universidad de Antioquia, UKE). Formalin-fixed samples from frontal, temporal, parietal, occipital cortex, and cerebellum were selected for morphological studies. Further studies of Aβ species were conducted in frontal cortices.

**Histopathological Methods**

All morphological analyses were performed on 3-μm-thick deparaffinized sections. Immunohistochemical stainings were performed following pre-treatment for antigen retrieval and probed with monoclonal anti-Aβ domain antibody (6E10,1:100, Covance, Maidenhead, United Kingdom) and anti pTau (pSer202 and pThr205) antibody (AT8, 1:1500, Thermo Scientific, Rockford, IL, United States). The following purified monoclonal antibodies against different Aβ species were used: Aβ x-38 (J&JPRD/Aβ38/5, 1:2000, Janssen Research & Development, Beerse, Belgium), Aβ x-40 (JRF/cAβ40/28, 1:1000, Janssen Research & Development, Beerse, Belgium), Aβx-42 (JRF/cAβ42/26, 1:1000, Janssen Research & Development, Beerse, Belgium), Aβ 1-43 (1:1000, Genetex, Irvine, CA, United States), and AβN3pE-x (J&JPRDAβ/pE3/1, 1:1000, Janssen Research & Development, Beerse, Belgium). Stainings were performed on an automated Ventana HX system (Ventana Medical Systems, Tucson, AZ, United States) following the manufacturer’s instructions. Experimental groups were stained in one run for each antibody in order to provide uniform staining conditions. Primary antibodies were visualized using a standard diaminobenzidine streptavidin-biotin horseradish.
TABLE 1 | Demographic profile of studied cases.

| Group           | Case | Gender | Age of Onset | Age of Death | Postmortem (h) | Brain Weight (g) | Braak | CERAD score | ApoE |
|-----------------|------|--------|--------------|--------------|----------------|------------------|-------|-------------|------|
| PS1-E280A FAD   | 1    | F      | 47           | 54           | 5.5            | 1029.0           | VI    | C           | 3/3  |
| PS1-E280A FAD   | 2    | M      | 44           | 52           | 4.8            | 1061.3           | VI    | C           | 3/3  |
| PS1-E280A FAD   | 3    | M      | 47           | 56           | 3.3            | 941.6            | VI    | C           | 3/3  |
| PS1-E280A FAD   | 4    | F      | 46           | 66           | 4.0            | 581.5            | VI    | C           | 3/4  |
| PS1-E280A FAD   | 5    | F      | 49           | 62           | 4.0            | 986.8            | VI    | C           | 3/3  |
| PS1-E280A FAD   | 6    | F      | 48           | 54           | 3.0            | 651.7            | VI    | C           | 3/3  |
| PS1-E280A FAD   | 7    | M      | 49           | 59           | 2.8            | 980.5            | VI    | C           | 4/4  |
| PS1-E280A FAD   | 8    | F      | 50           | 60           | 2.8            | 788.1            | VI    | C           | 3/3  |
| PS1-E280A FAD   | 9    | F      | 52           | 68           | 6.4            | 763.3            | VI    | C           | 3/3  |
| PS1-E280A FAD   | 10   | F      | 47           | 58           | 3.5            | 937.2            | VI    | C           | 3/3  |
| Mean/% (SD)     | 60%  | 47.9 (2.2) | 58.5 (5.4)   | 4.0 (1.2)  | 868.3 (165.4) | 100%  | 100% | 20%          |
| SAD             | 11   | M      | ND           | 67           | 10             | 1225.0           | V     | C           | 3/3  |
| SAD             | 12   | M      | 80           | 86           | 6.3            | 1200.0           | IV    | C           | ND   |
| SAD             | 13   | F      | 55           | 70           | 11.3           | 890.0            | IV    | B           | 3/4  |
| SAD             | 14   | F      | 79           | 87           | 2.8            | 642.8            | V     | C           | 3/4  |
| SAD             | 15   | F      | 82           | 91           | 4.5            | 956.0            | VI    | C           | 3/3  |
| SAD             | 16   | F      | 65           | 74           | 2.5            | 846.0            | IV    | C           | 3/3  |
| SAD             | 17   | F      | 65           | 76           | 4.3            | ND               | V     | C           | 4/4  |
| SAD             | 18   | F      | 69           | 76           | 8.0            | ND               | VI    | C           | 3/4  |
| SAD             | 19   | M      | 70           | 83           | 4.3            | 981.1            | VI    | C           | 3/2  |
| SAD             | 20   | F      | 50           | 61           | 4.1            | ND               | VI    | C           | 3/3  |
| Mean/% (SD)     | 70%  | 68.3 (11.0) | 77.1 (9.6)   | 5.81 (3.0) | 991.5         | 40%   | 90%  | 40%          |
| t test/c2 value | 0.22 | ~3.56   | ~3.48        | ~1.36       | ~1.07         | 8.57  | 1.05 | 1.31         |
| p               | 1.000 | 0.000*** | 0.001***     | 0.173       | 0.283         | 0.003** | 1.000 | 0.252        |

peroxidase method (Sigma Aldrich, Hamburg, Germany). Amyloid plaques were assessed and classified according to standard criteria (Duyckaerts et al., 2009). For quantification of primary antibodies immunosignal, three representative regions (0.1349 mm² each) were analyzed by quantifying the area immunoreactive for Aβ as a percentage of the total area for each image using the AxioVision 4.6 software (Carl Zeiss, Oberkochen, Germany) according to published methods (Debatin et al., 2008). We evaluated cerebral amyloid angiopathy (CAA) in SAD and FAD cases alongside the Vonsattel grading scale (Vonsattel et al., 1991), as the percentage of vessels identified with more than two thirds of their perimeter immunostained for specific Aβ antibodies in the frontal cortex. Twenty vessels were evaluated per patient.

Biochemical Methods
Solid phase sandwich enzyme-linked immunosorbent assay (ELISA) for Aβ 1-40 and Aβ 1-42 (Invitrogen, Camarillo, CA, United States) and that for Aβ 1-38 and Aβ 1-43 (IBL, Hamburg, Germany) were used according to manufacturer protocols. Briefly, 100 mg of snap-frozen tissue from frontal cortices were homogenized in 800 ml of 5 M guanidine HCl/50 mM Tris–HCl for Aβ solubilization as reported (Selkoe, 1994; Cotman, 1997). Homogenates were mixed for 4 h at room temperature, diluted in phosphate-buffered saline/5% bovine serum albumin/0.03% Tween 20, and centrifuged at 16,000 × g for 20 min at 4°C. Supernatant was collected and probed with the ELISA kit for each antigen. Samples were measured at 450 nm in a BioTek mQuant spectrophotometer (Winooski, VT, United States) and expressed as pmol/mg of total protein.

Statistical Analysis
Data were analyzed using IBM SPSS Statistics 22 software (IBM/SPSS Inc., Armonk, NY, United States) and GraphPad Prism 6 (GraphPad Software, Inc., La Jolla, CA, United States). Analyses included Kolmogorov–Smirnov and Shapiro–Wilk tests for normal distribution assessment. For non-parametric comparisons, we applied Mann–Whitney U (given as Z) for two group comparisons and Chi square test was applied to categorical variables. Correlation analysis was performed using Spearman Rho’s test. Statistical significance of all analyses was determined with *p ≤ 0.05, **p ≤ 0.01, and ***p ≤ 0.001.

RESULTS
Similar Morphology and Distribution of 6E10 Detected Aβ Pathology in SAD and PS1 E280A FAD
Detected Aβ immunosignal in FAD did not differ significantly from SAD in all five brain regions studied (Figures 1A,B). Both SAD and FAD cases showed diffuse, core, and neuritic
Aβ plaques. FAD cases present with abundant diffuse plaques, as previously described (Shepherd et al., 2009). SAD cases also showed abundant diffuse plaques, particularly in frontal and temporal cortices. There was high variability in the size and distribution of plaques in both groups and studied group regions (Figure 1A). The highest average immunosignal was detected in the frontal cortex of FAD as well as of SAD patients, followed by temporal cortex, parietal cortex, and occipital cortex, with the lowest Aβ signal being detected in the cerebellum (Figure 1B and Table 2), creating a predominantly frontal aggregation pattern (Figure 1C). When individual aggregation patterns were analyzed, we found that 5/10 SAD and 7/10 FAD cases showed frontal cortex predominance. Two out of 10 SAD showed temporal cortex predominance while 2/10 FAD showed parietal cortex predominance (Figure 1D).

**Differential pTau Pathology and Increased AT8 Immunosignal in PS1 E280A FAD**

It has been previously suggested that Aβ aggregation drives pTau pathology in AD (Stancu et al., 2014). Both SAD and FAD groups presented with abundant pTau AT8 diffuse signal...
TABLE 2 | Comparative analysis for Aβ peptides and pTau immunosignal.

| Variable                           | PS1-E280A FAD       | SAD           | Value       | p     |
|------------------------------------|---------------------|---------------|-------------|-------|
|                                    | Mean                | SD            | Mean        | SD    |
| **6E10 Immunosignal Area (mm²)**   |                     |               |             |       |
| Frontal Cortex                     | 56,092.62           | 7305.29       | 47,757.28   | 8995.46 | −1.134 | 0.257 |
| Temporal Cortex                    | 32,339.89           | 7551.81       | 36,753.58   | 8307.88 | −0.302 | 0.762 |
| Parietal Cortex                    | 34,300.06           | 7083.65       | 20,753.3    | 4648.34 | −1.285 | 0.199 |
| Occipital Cortex                   | 25,884.29           | 3837.6        | 22,181.8    | 5235.15 | −0.907 | 0.364 |
| Cerebellum                         | 6235.14             | 1410.49       | 3619.2      | 1351.57 | −1.285 | 0.199 |
| **AT8 Immunosignal Area (mm²)**    |                     |               |             |       |
| Frontal Cortex                     | 182,242.41          | 15,791.27     | 96,201.68   | 18,382.56 | −1.89  | 0.059 |
| Temporal Cortex                    | 175,241.61          | 14,731.02     | 150,853.68  | 11,620.95 | −0.756 | 0.450 |
| Parietal Cortex                    | 175,502.72          | 21,045.91     | 120,702.06  | 22,280.09 | −1.663 | 0.096 |
| Occipital Cortex                   | 202,518.61          | 15,726.26     | 145,855.3   | 15,004.9 | −2.041 | 0.041*|
| Cerebellum                         | 178.99              | 59.29         | 36.62       | 19.85  | −2.117 | 0.034*|
| **Immunosignal Area (mm²) in Frontal Cortex** |               |               |             |       |
| Aβ 1-38                            | 133,778.76          | 59,511.88     | 685,023.95  | 71,017.07 | −3.326 | 0.001**|
| Aβ 1-40                            | 98,008.09           | 12,188.78     | 128,683.57  | 53,115.09 | −0.907 | 0.364 |
| Aβ 1-42                            | 199,059.23          | 16,922.21     | 160,329.22  | 22,249.32 | −2.268 | 0.023*|
| Aβ 1-43                            | 37,831.11           | 8134.32       | 305,449.17  | 136,139.17 | −2.343 | 0.019*|
| Pyroglutamylated Aβ 3pE-x           | 321,872.71          | 34,202.97     | 306,876.82  | 60,287.35 | −0.454 | 0.65 |
| **Area Ratios in Frontal Cortex**   |                     |               |             |       |
| Aβ 1-38/1-42                       | 0.65                | 0.25          | 4.58        | 0.84  | −3.628 | 0.0001***|
| Aβ 1-42/1-40                       | 2.19                | 0.27          | 2.29        | 0.67  | −0.151 | 0.880 |
| Aβ 1-40/1-43                       | 3.35                | 0.68          | 2.3         | 2.07  | −2.797 | 0.005**|
| **ELISA values in Frontal Cortex (pmol/g)** |               |               |             |       |
| Aβ 1-38                            | 22.21               | 8.59          | 52.67       | 31.83 | 0.000  | 1.00 |
| Aβ 1-40                            | 121.16              | 58.28         | 113.56      | 71.21  | −0.227 | 0.821 |
| Aβ 1-42                            | 522.21              | 147.28        | 161.01      | 40.32  | −2.57  | 0.01**|
| Aβ 1-43                            | 9.1                 | 4.93          | 2.67        | 1.01  | −1.739 | 0.082 |
| **ELISA Ratios in Frontal Cortex**  |                     |               |             |       |
| Aβ 1-38/1-42                       | 0.05                | 0.01          | 0.41        | 0.28  | −1.361 | 0.174 |
| Aβ 1-42/1-40                       | 11.05               | 4.74          | 6.28        | 4.22  | −1.587 | 0.112 |
| Aβ 1-40/1-43                       | 24.01               | 10.33         | 8.06        | 28.73  | −1.739 | 0.082 |

and aggregates (Figure 2A). We found significantly elevated levels of pTau in FAD compared to SAD in occipital cortex, which represented the most affected brain region in both groups. Lowest pTau signals were observed in cerebellum, whereas previously described (Sepulveda-Falla et al., 2011) FAD cases showed significantly more signal than SAD cases (Figure 2B and Table 2). As with Aβ, we analyzed pTau pathology distribution patterns, with average patterns showing a similar predominance of temporal and occipital cortices signal (Figure 2C). Regarding individual patterns, 3/10 SAD and 2/10 FAD cases showed parietal predominance. Four out of 10 SAD and 1/10 FAD cases showed temporo-occipital predominant pattern, while temporal (3/10) and occipital (4/10) predominant patterns were identified in FAD. Interestingly, two FAD cases showed high deposits in all cortices but in the temporal cortex (Figure 2D). Given that general deposition patterns for Aβ and pTau did not show clear differences between SAD and FAD, we analyzed the correlations between both signals for each of the studied regions. Besides the correlation between Aβ in cerebellum and pTau in parietal cortex, no significant correlations between 6E10 and AT8 immunosignals for any other evaluated regions were observed (Supplementary Figure S1 and Supplementary Table S1).

**Characteristic Aβ Species Profile in the Frontal Cortex of PS1 E280A FAD and SAD Patients**

Given that APP processing and Aβ production are thought to be main features in FAD (Moro et al., 2012), we analyzed deposition of specific Aβ species in frontal cortices of both AD groups (Figures 3A,B). Aβ 1-38 and Aβ 1-43 showed statistically significant higher levels, while Aβ 1-42 showed statistically significant lower levels in SAD compared to FAD. No differences between FAD and SAD were found for Aβ 1-40 (Figures 4A,B). It has been suggested that differences in Aβ ratios can be pathologically relevant (Pauwels et al., 2012). By calculating the Aβ 1-38/1-42, the Aβ 1-42/1-40, and the Aβ 1-40/1-43 ratios, we found significantly higher values in SAD for Aβ 1-38/1-42, and higher values in FAD than in SAD for Aβ
40/43. Aβ 1-42/1-40 ratio showed no difference between both AD groups (Figure 4C).

Given that IHC staining shows only visible accumulation of Aβ, we performed ELISA for each species (Figure 3B). FAD showed significantly higher amount of Aβ 1-42 in the frontal cortex. In contrast to IHC, the other species (1-38, 1-40, and 1-43) showed no significant differences between groups (Figure 5A). Likewise, there were no significant differences of Aβ ratios in FAD compared to SAD (Figure 5B).
Characterization of Pyroglutamyated Aβ and CAA Pathology in PS1 E280A FAD

We tested one specific antibody against Pyroglutamyated Aβ 3 to 40-42 (Pyroglu. Aβ 3pE-x) in frontal cortex of SAD and FAD cases. We detected equally strong amyloid pathology in both groups (Figure 6A). The Pyroglu. Aβ 3pE-x antibody showed strong signal in the vessels of both SAD and FAD cases (Figure 6B). Previously, it has been reported that FAD presents with higher CAA scores than SAD (Ringman et al., 2016). We evaluated CAA pathology using Aβ 1-42 and the Pyroglu. Aβ 3pE-x antibodies. We focused on the number of vessels that presented grade 3 CAA pathology assessed according to the Vonsattel grading system (Vonsattel et al., 1991). For both antibodies, there were no statistically significant differences in severe CAA pathology between groups (Figures 6B,C). When an Aβ 1-42/Pyroglu. Aβ 3pE-x ratio was calculated for severe CAA affected vessels, SAD cases presented a statistically significant higher CAA Aβ 1-42/Pyroglu. Aβ 3pE-x ratio when compared to FAD cases (Figure 6C).

DISCUSSION

Previously we reported specific neuropathological differences between FAD and early onset SAD, with increased 6E10 positive Aβ levels in the frontal cortex and cerebellum of PS1 E280A FAD cases (Sepulveda-Falla et al., 2011), and some Aβ morphological differences in another subset of PS1 E280A patients (Trujillo-Rodríguez et al., 2014). In the present study, we observed no statistically significant differences in 6E10 positive signal from all brain cortices and cerebellum between PS1 E280A FAD cases and similarly, affected SAD cases. It should be kept in mind that 6E10 antibody also stains full length APP containing Aβ domain. However, since antibody positive signal referred specifically to plaques, only pathologic deposits were evaluated. It is possible that early-onset SAD cases might have lower Aβ levels when compared with later-onset SAD (Wolfe, 2007). Both AD groups showed increased Aβ pathology in the frontal cortex, also as a predominant pattern among individuals. This result is in agreement with previous findings regarding Aβ pathology in AD according to PET studies in SAD cases (Barthel et al., 2011) and may reflect region-specific susceptibility toward Aβ pathology (Braak and Del Trecidi, 2011; Thal et al., 2015). It has been reported that Aβ pathology in PS1 FAD is characterized by a diffuse pattern (Shepherd et al., 2009). Our set of severely affected SAD cases showed a similarly, extended diffuse pattern indistinguishable from the observed pattern in FAD when using 6E10A antibody.

Regarding AT8-detected pTau pathology, PS1 E280A FAD showed statistical significance only in the occipital cortex and cerebellum; this last feature was as previously reported (Sepulveda-Falla et al., 2011). On an individual basis, predominantly affected areas differ between SAD and FAD, suggesting a differential pTau pathological process between FAD and SAD (Sepulveda-Falla et al., 2011; Trujillo-Rodriguez et al., 2014). PS1 mutations affect the activation of kinase cascades (Baki et al., 2008), which could explain this difference. Finally, the lack of correlation between Aβ and pTau pathology in both
FAD and SAD confirms previous findings about independent pathology processes in AD (Braak and Del Trecidi, 2011). It has been suggested that in SAD, pTau pathology could precede Aβ plaque deposition. Given that FAD is caused by γ secretase dysfunction, Aβ pathology should precede pTau pathology; the fact that pTau aggregation patterns show no association with the Aβ aggregation pattern suggests that other events independent of Aβ production may be involved in FAD.

Presenilin-1 mutations affect γ secretase activity, shifting the type of Aβ peptides generated. An alternating forked model

**FIGURE 4** | Aβ peptide species pathology profile in SAD and PS1 E280A FAD. (A) Immunohistochemical staining for Aβ 1-38, 1-40, 1-42, and 1-43 in FC of SAD and FAD cases (scale bar is 200 mm). Insets depict Aβ deposits at higher magnification (scale bar = 70 mm). (B) Quantification of immunosignals for Aβ 1-38, 1-40, 1-42, and 1-43. Significantly higher levels of Aβ 1-38 and 1-43 together with significantly lower levels of Aβ 1-42 were found in SAD when compared to FAD. ∗p ≤ 0.05; ∗∗p ≤ 0.01. (C) Aβ 1-38/1-42, Aβ 1-42/1-40, and Aβ 1-40/1-43 calculated ratios. SAD cases showed significantly higher Aβ 1-38/1-42 ratio and significantly lower Aβ 1-40/1-43 ratio than FAD cases. Cases crossed by a line are outliers that were not taken in consideration for statistical analysis. ∗∗∗p ≤ 0.01. **p ≤ 0.05; ***p ≤ 0.001.
for the successive epsilon cut of C99 APP fragment has been proposed, in which γ secretase generates either Aβ 1-46 > 1-43 > 1-40 or Aβ 1-45 > 1-42 > 1-38 peptides (Chávez-Gutiérrez et al., 2012; Golde et al., 2013). It has been shown in PS1 E280A cellular models that the Aβ 1-42/1-40 ratio is decreased, by decreasing Aβ-1-42 to Aβ 1-38 turnover (Li et al., 2016). We recently characterized Aβ peptide production by purified gamma secretase from postmortem brain tissue from several pS1 mutations. PS1 E280A showed decreased Aβ 1-38, Aβ 1-40, and total Aβ, together with increased Aβ 1-42/Aβ 1-40 ratio and decreased Aβ 1-38/Aβ 1-42 ratio when compared to SAD and controls (Szaruga et al., 2017).

For analyzing morphology and distribution of Aβ 1-38, 1-40, and 1-42 peptides, we used a set of antibodies developed by Janssen R&D [43] and characterized by high specificity and sensitivity. We identified a clear and complementary difference of Aβ 1-38 and Aβ 1-42 immunosignals in frontal cortex between FAD and SAD cases, suggesting that mutated PS1 favors Aβ 1-42 over Aβ 1-38 production, confirming previous findings (Szaruga et al., 2017). Even though increased Aβ 1-42 immunosignal in this population (Lemere et al., 1996) and in FAD in general (Kumar-Singh et al., 2006) has been widely reported, decreased 1-38 signal is a novel neuropathological finding in agreement with altered γ secretase function as described in vitro for PS1 FAD (Chávez-Gutiérrez et al., 2012; Szaruga et al., 2017) and in contrast to a recent report studying 1-38 pathology in APP, PS1, and PS2 FAD cases comparing them with SAD. In that report, neither PS1 mutant carriers nor SAD cases without CAA presented with Aβ 1-38 pathology. The PS1 E280A mutation was not included (Moro et al., 2012). In our study all severely affected SAD cases showed higher Aβ 1-38 loads when compared to PS1 E280A FAD. The differences between studies could be explained by the severity of studied SAD patients and specificity/sensitivity of the antibodies used.

Regarding Aβ 1-43 and 1-40 immunosignal, only Aβ 1-43 showed higher levels in SAD. Previous reports in human brain tissue indicated Aβ 1-43 to be more frequently observed in the core of Aβ plaques (Welander et al., 2009) and to accumulate more than Aβ 1-40 in SAD brains (Saito et al., 2011). It is to be noted that in the first study only one case of PS1 FAD was investigated. Furthermore, by evaluating Aβ 1-38/1-42 and Aβ 1-40/1-43 ratios, we confirm cell culture-based studies suggesting FAD-specific Aβ production (Chávez-Gutiérrez et al., 2012). Higher levels of Aβ 1-38 and Aβ 1-43 are favored in SAD while Aβ 1-42 production is specifically increased in FAD. Interestingly, the Aβ 1-42/1-40 ratio showed no difference between FAD and SAD cases, which is in opposition to previous findings (Kumar-Singh et al., 2006). This ratio could vary depending on PS1 mutation and on AD pathology severity of the SAD cases studied. Recently, the pathogenicity of Aβ 1-43 in FAD has come to the fore. It has been described that increased production of Aβ 1-43 in specific PSI FAD mutations is a reflection of increased γ secretase dysfunction (Trambauer et al., 2020). Perhaps low Aβ 1-43 levels detected in our FAD samples are related with the
FIGURE 6 | Pyroglutamylated Aβ peptide pathology profile in SAD and PS1 E280A FAD. (A) Immunohistochemical staining for Pyroglutamylated Aβ 3pE-x in FC of SAD and FAD patients (scale bar = 200 mm). Insets depict Pyroglutamylated Aβ 3pE-x deposits at higher magnification (scale bar = 70 mm). Quantification of immunosignal for Pyroglutamylated Aβ in both groups. No differences were observed between groups. (B) Characterization of Aβ cerebral amyloid angiopathy (CAA) using a specific Aβ 1-42 antibody (as seen in Figure 3). Both, SAD and FAD cases present with severe CAA, with similar percentage of vessels affected in two thirds of their perimeter (% of +++ vessels, n = 20). (C) Characterization of CAA using a Pyroglutamylated Aβ 3pE-x antibody (as seen in Figure 3). Both SAD and FAD cases present with severe CAA, with similar percentage of vessels affected in two thirds of their perimeter (% of +++ vessels, n = 20).

relatively mild γ-secretase dysfunction observed in PS1 E280A brain homogenates (Szaruga et al., 2015).

One possible objection for morphological differences in Aβ species detection could be that observed changes represent the endpoint of Aβ pathology (Serrano-Pozo et al., 2012). Thus, we evaluated Aβ species by ELISA. Aβ 1-38, 1-40, and 1-42 results resemble our histological findings. None of the calculated Aβ ratios (as measured by ELISA) were significantly different as opposed to histological findings and in contrast to some of our previous results obtained with less severely affected SAD cases (Sepulveda-Falla et al., 2012). Furthermore, Aβ as detected by ELISA may not be identical to Aβ detected by in situ methods. Aβ deposits can reflect long-term Aβ pathology better because only a continuous phenomenon could generate them, whether by increased production or impaired degradation. We propose that Aβ 1-38/1-42 and Aβ 1-40/1-43 ratios as assessed by immunohistochemistry are a sensitive enough tool for the neuropathological study of both AD groups. Our study
shows Aβ species profile in only one PS1 mutation. Other PS1 mutations could present with different Aβ species profiles. However, among PS1 mutations, there are common features such as Aβ 1-38/1-42 ratio (Li et al., 2016; Szaruga et al., 2017) that could result in similar IHC findings.

Post-translational modifications of Aβ, like pyroglutamylated and truncated forms, deposit alongside other Aβ species (Cabrera et al., 2018). Pyroglu. Aβ 3pE-x have been identified as depositing early in humans and primates while depositing later in transgenic mouse models (Frost et al., 2013). It seems to be specifically associated with AD pathology in contrast to age-associated Aβ deposits (Moro et al., 2018), or to pure CAA (Gkanatsiou et al., 2019). In our analysis, both severely affected SAD and PS1 E280A FAD frontal cortices showed equally extensive Pyroglu. Aβ 3pE-x plaque and vessel pathology. However, Pyroglu. Aβ 3pE-x antibody detected relatively more severely affected vessels in FAD than those detected with Aβ 1-42 antibody. This difference could be related with the temporal order in which different Aβ species are deposited in SAD and FAD. For FAD, higher Aβ 1-42 generation is constant throughout life, while Pyroglu. Aβ 3pE-x deposits can be associated with aging (Moro et al., 2018). Further studies should assess if truncated Aβ species play a larger role in CAA in PS1 FAD. Besides, vascular impact of Pyroglu. Aβ 3pE-x aggregation can be of relevance given the possible use of pyroglutamylated Aβ detection in plasma as a biomarker for plaque pathology in AD (Wang et al., 2020).

We have previously reported neuropathological differences between PS1 E280A FAD and SAD cases, including differential pTau pathology (Sepulveda-Falla et al., 2011), distinct APP processing patterns (Pera et al., 2013), and mitochondrial damage and decreased Ca2+ channels in the cerebellum (Sepulveda-Falla et al., 2014). In this study, we describe yet another difference between PS1 E280A FAD and SAD, regarding Aβ pathology and possibly linked to the underlying γ secrete dysfunction in PS1 FAD cases. We propose the usage of specific Aβ 1-38, 1-40, 1-42, and 1-43 antibodies and their immunosignal values and ratios as a viable option for better assessment of FAD cases and the identification of SAD cases with similarly, altered Aβ production to be studied further.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article can be made available by the corresponding author upon reasonable request.

REFERENCES

Acosta-Baena, N., Sepulveda-Falla, D., Lopera-Gómez, C. M., Jaramillo-Elorza, M. C., Moreno, S., Aguirre-Acevedo, D. C., et al. (2011). Pre-dementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer’s disease: a retrospective cohort study. Lancet Neurol. 10, 213–220. doi: 10.1016/s1474-4422(10)70323-9

Adamczuk, K., Schaeverbeke, J., Vanderstichele, H. M. J., Lilja, J., Nelissen, N., Van Laere, K., et al. (2015). Diagnostic value of cerebrospinal fluid Aβ ratios in preclinical Alzheimer’s disease. Alzheimers Res. Ther. 7:75.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Comité de Bioética, Facultad de Medicina, Universidad de Antioquia. Acta número 011 de 2016. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

FD, DT-R, and DS-F performed the experiments. FD, JS, MM, MG, and DS-F set up the experimental design. FD, AV, DT-R, FL, and DS-F were involved in data and or patient material acquisition. FD, MG, and DS-F wrote the manuscript and was revised by all authors.

FUNDING

This work was supported by the Hamburg State Ministry for Science and Research, Landesforschungsförderung “Molekulare Mechanismen der Netzwerkmodifizierung” and by the Federal Ministry of Education and Research, project Undo AD, to MG and DS-F, and by the Universidad de Antioquia and Colciencias grant 11155431651 contract 419-2011 to FL.

ACKNOWLEDGMENTS

The authors would like to thank Dr. Hermann Altmeppen for manuscript proofreading and the Colombian families affected by PS1 E280A. Early Onset Familial Alzheimer’s disease for their continuous support.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnagi.2020.00220/full#supplementary-material

Alzheimer’s Association (2010). Alzheimer’s disease facts and figures. Alzheimers Dement. 6, 158–194. doi: 10.1016/j.jalz.2010.01.009

Baki, L., Neve, R. L., Shao, Z., Shiou, J., Georgakopoulos, A., and Robakis, N. K. (2008). Wild-type but not FAD mutant presenilin-1 prevents neuronal degeneration by promoting phosphatidylinositol 3-kinase neuroprotective signaling. J. Neurosci. 28, 483–490. doi: 10.1523/jneurosci.4067-07.2008

Barthel, H., Gertz, H.-J., Dresel, S., Peters, O., Bartenstein, P., Buerger, K., et al. (2011). Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer’s disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 10, 424–435. doi: 10.1016/s1474-4422(11)70077-1

Bakir, T., Giacobini, E., and Van Laere, K. (2015). Diagnostic value of cerebrospinal fluid Aβ ratios in preclinical Alzheimer’s disease. Alzheimers Res. Ther. 7:75.
Berr, C., Wancata, J., and Ritchie, K. (2005). Prevalence of dementia in the elderly in Europe. Eur. Neuropsychopharmacol. 15, 463–471. doi: 10.1016/j.euroneuro.2005.04.003

Bertram, L., Lill, C. M., and Tanzi, R. E. (2010). The genetics of Alzheimer disease: back to the future. Neuron 68, 278–281. doi: 10.1016/j.neuron.2010.10.013

Betens, K., Sleegers, K., and Van Broeckhoven, C. (2013). Genetic insights in Alzheimer’s disease. Lancet Neurol. 12, 92–104.

Braak, H., and Braak, E. (1991). Neuropathological staging of Alzheimer-related changes. Acta Neuropathol. 82, 239–259. doi: 10.1007/bf00388089

Braak, H., and Del Tredici, K. (2011). Neuroanatomy and pathology of sporadic Alzheimer’s disease. Adv. Anat. Embryol. Cell Biol. 215, 1–162.

Burnouf, S., Gorsky, M. K., Dols, J., Grönke, S., and Partridge, L. (2015). Aβ43 is neurotoxic and primes aggregation of Aβ40 in vivo. Acta Neuropathol. 130, 35–47. doi: 10.1007/s00401-015-1419-y

Cabrera, E., Mathews, P., Mechericher, E., Beach, T. G., Deng, J., Neubert, T. A., et al. (2018). Aβ truncated species: implications for brain clearance mechanisms and amyloid plaque deposition. Biochim. Biophys. Acta Mol. Basis Dis. 1864, 208–225. doi: 10.1016/j.bbadis.2017.07.005

Chávez-Gutiérrez, L., Bammens, L., Benllova, I., Vandersteent, A., Benurwar, M., and Borgers, M., et al. (2012). The mechanism of γ-secretase dysfunction in familial Alzheimer disease. EMBO J. 31, 2261–2274. doi: 10.1038/emboj.2012.79

Cotman, C. W. (1997). The beta-amyloid peptide, peptide self-assembly, and the emergence of biological activities. A new principle in peptide function and the induction of neuropathology. Annu. N. Y. Acad. Sci. 814, 1–16. doi: 10.1111/j.1749-6632.1997.tb41640.x

Cruts, M., Thieme, K., and Van Broeckhoven, C. (2012). Locus-specific mutation databases for neurodegenerative brain diseases. Hum. Mutat. 33, 1340–1344. doi: 10.1002/humu.22117

De Strooper, B., and Annaert, W. (2010). Novel research horizons for presenilins and gamma-secretases. EMBO J. 29, 5186–5196. doi: 10.1002/emboj.201000311

Dolby, A., Thompson, J., Gómez-Isla, T., Burnouf, S., Gorsky, M. K., Dols, J., Grönke, S., and Partridge, L. (2013). Genetic insights in Alzheimer’s disease. Lancet Neurol. 12, 92–104.

Frontiers in Aging Neuroscience | www.frontiersin.org 12 July 2020 | Volume 12 | Article 220

Giaccone, G., Arzberger, T., Alafuzoff, I., Al-Sarraj, S., Budka, H., Duyckaerts, C., Burnouf, S., Gorsky, M. K., Dols, J., Grönke, S., and Partridge, L. (2015). Aβ Braak, H., and Braak, E. (1991). Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239–259. doi: 10.1007/bf00388089

Gómez-Isla, T., et al. (2015). Novel research horizons for presenilins and γ-secretases. EMBO J. 29, 5186–5196. doi: 10.1002/emboj.201000311

Golde, T. E., Koo, E. H., Felsenstein, K. M., Osborne, B. A., and Miele, L. (2008). Association between deposition of beta-amyloid and pathological prion protein in sporadic Creutzfeldt-Jakob disease. Neurology 235–260. doi: 10.1146/annurev.cellbio-100109-104117

Götzl, I., Hauser, I., Giaconi, G., Lombardi, R., Indaco, A., Uggetti, A., Morfin, B., et al. (2012). Apolipoprotein E epsilon4 association with dementia in a population-based study: the framingham study. Neurology 46, 673–677. doi: 10.1212/wnl.0b013e31825f7d73

Hauri, P., and Mayeur, R. (2008). Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem. Pharmacol. 87, 640–651. doi: 10.1016/j.bcp.2007.06.017

Hurst, C., and Marchesi, V. (2016). Presenilin-dependent regulated intramembrane proteolysis and gamma-secretase activity. Cell Mol. Life Sci. 73, 1534–1555. doi: 10.1007/s00018-015-4835-9

Hurst, C., and Marchesi, V. (2016). Presenilin-dependent regulated intramembrane proteolysis and gamma-secretase activity. Cell Mol. Life Sci. 73, 1534–1555. doi: 10.1007/s00018-015-4835-9

Kumar-Singh, S., Theuns, J., Van Broeck, B., Pirici, D., Vennekens, K., Corsmit, E., et al. (2006). Mean age-of-onset of familial alzheimer disease caused by presenilin mutations correlates with both increased Abeta42 and decreased Abeta40. Hum. Mutat. 27, 686–695. doi: 10.1002/humu.20336

Larner, A. J. (2013). Presenilin-1 mutations in Alzheimer’s disease: an update on genotype-phenotype relationships. J. Alzheimers Dis. 37, 653–659. doi: 10.3233/jad-130746

Lemere, C. A., Lopera, F., Kosik, K. S., Lendon, C. L., Ossa, J., Saido, T. C., et al. (1996). The E280A presenilin 1 Alzheimer mutation produces increased A beta 42 deposition and severe cerebellar pathology. Nat. Med. 2, 1146–1150. doi: 10.1016/nm1096-1146

Li, N., Liu, K., Qiu, Y., Ren, Z., Dai, R., Deng, Y., et al. (2016). Effect of presenilin mutations on AβPP cleavage; insights into the pathogenesis of FAD. Front. Aging Neurosci. 8:51. doi: 10.3389/fnagi.2016.00501

McCarty, J. V., Twomey, C., and Wuiek, P. (2009). Presenilin-dependent regulated intramembrane proteolysis and gamma-secretase activity. Cell Mol. Life Sci. 66, 1534–1555. doi: 10.1007/s00018-015-4835-9

McKerracher, L., and Wijker, A. (2009). γ-secretase and amyloid-beta metabolism: the long and “folded” road to understand the mechanism. Mol. Neurodegener. 9:51. doi: 10.1186/1750-1326-9-51
Szuruga, M., Munteanu, B., Lismont, S., Veugelen, S., Horré, K., Mercken, M., et al. (2017). Alzheimer’s-causing mutations shift Aβ length by destabilizing γ-secretase-Aβn Interactions. Cell 170, 443.e14–456.e14.

Szuruga, M., Veugelen, S., Benuwar, M., Lismont, S., Sepulveda-Falla, D., Lleo, A., et al. (2015). Qualitative changes in human γ-secretase underlie familial Alzheimer’s disease. J. Exp. Med. 212, 2003–2013. doi: 10.1084/jem.20150892

Thal, D. R., Walter, J., Saito, T. C., and Fändrich, M. (2015). Neuropathology and biochemistry of Aβ and its aggregates in Alzheimer’s disease. Acta Neuropathol. 129, 167–182. doi: 10.1007/s00401-014-1375-y

Trambauer, J., Rodriguez Sarmiento, R. M., Fukumori, A., Feederle, R., Baumann, K., and Steiner, H. (2020). Aβ43-producing PS1 FAD mutants cause altered substrate interactions and respond to γ-secretase modulation. EMBO Rep. 21:e47996.

Trujillo-Rodríguez, D. M., Sepúlveda-Falla, D., Arboleda, H., Glatzel, M., and Lopera, F. (2014). Neuropathological, neuropsychological, and imagingological comparison between sporadic Alzheimer’s disease and ps1-e280a. Alzheimer’s Dementia J. Alzheimer’s Assoc. 10:476.

Van Vickle, G. D., Esh, C. L., Kokjohn, T. A., Patton, R. L., Kalback, W. M., Luehrs, D. C., et al. (2008). Presenilin-1 280Glu→Ala mutation alters C-terminal APP processing yielding longer abeta peptides: implications for Alzheimer’s disease. Mol. Med. 14, 184–194. doi: 10.2119/2007-00094.vanvickle

Vonsattel, J. P., Myers, R. H., Hedley-Whyte, E. T., Ropper, A. H., Bird, E. D., and Richardson, E. F. (1991). Cerebral amyloid angiopathy without and with cerebral hemorrhages: a comparative histological study. Ann. Neurol. 30, 637–649. doi: 10.1002/ana.410300503

Wakabayashi, T., and De Strooper, B. (2008). Presenilins: members of the gamma-secretase quartets, but part-time soloists too. Physiology 23, 194–204. doi: 10.1152/physiol.0009.2008

Wang, P.-N., Lin, K.-J., Liu, H.-C., Andreasson, U., Blennow, K., Zetterberg, H., et al. (2020). Plasma pyroglutamate-modified amyloid beta differentiates amyloid pathology. Alzheimers Dement 12:e12029.

Welander, H., Frånberg, J., Graff, C., Sundström, E., Winblad, B., and Tjernberg, L. O. (2009). Abeta43 is more frequent than Abeta40 in amyloid plaque cores from Alzheimer disease brains. J. Neurochem. 110, 697–706. doi: 10.1111/j.1471-4159.2009.06170.x

Wolfe, M. S. (2007). When loss is gain: reduced presenilin proteolytic function leads to increased Abeta42/Abeta40. Talking Point on the role of presenilin mutations in Alzheimer disease. EMBO Rep. 8, 136–140. doi: 10.1038/sj.embor.7400896

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Dinkel, Trujillo-Rodriguez, Villegas, Streffer, Mercken, Lopera, Glatzel and Sepulveda-Falla. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.